The composition may be used alone or as an adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox.
TapImmune said the transporters associated with antigen presentation (TAP) technology can improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.
TapImmune chairman and CEO Glynn Wilson said USPTO has added another important piece to their intellectual property portfolio.
"It provides protection for the development of new products in the prophylactic and biodefense vaccine markets," Wilson said.